Sumitomo Chemical India FY26: Stability, Mix Gains and a Bigger Capex Agenda

FY26 consolidated revenue from operations was INR 3,238.3 crore (up 3% YoY), EBITDA was INR 670.9 crore (margin 20.7%), and net profit was INR 543.0 crore (margin 16.8%), as per the investor presentation.

Q4 FY26 revenue from operations was INR 683.7 crore (up 1% YoY). EBITDA was INR 134.2 crore (up 12% YoY) and PAT was INR 111.3 crore (up 12% YoY), per the consolidated P&L table.

FY26 mix in the presentation: Insecticides 41%, Herbicides 24%, PGR 9%, Metal Phosphides 9%, Fungicides 8%, and AND and EHD 9%.

Key items include a Dahej herbicide intermediate plant (capex about INR 150 crore, estimated commercialization Q2 FY2028-29) and a Tarapur fitment for two molecules (capex about INR 10 crore, estimated commercialization Q4 FY2027-28). The presentation also cited Bhavnagar and Tarapur projects targeted for Q4 FY27.

The presentation stated cash, cash equivalents and liquid investments of about INR 2,113 crore as of 31 March 2026.

The company disclosed board and leadership reconstitution effective 1 September 2026, including Dr. Suresh Ramachandran proposed to be appointed as Managing Director, and Mr. Chetan Shah’s MD term ending on 31 August 2026 with a proposed move to a non-executive role, subject to shareholder approvals.